Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosamprenavir in PPI-Refractory GERD
NCT06704100Phase 2Not yet recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Oct 2027
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fosamprenavir in gastroesophageal reflux disease (GERD), sponsored by Medical College of Wisconsin. Planned start Oct 2027; status: not yet recruiting.
02
Drugs
fosamprenavir
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06704100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704100.